Safety and Efficacy of Platelet-Rich Plasma Combined With Compound Betamethasone in Arthroscopic Surgery for Rotator Cuff Injury With Shoulder Adhesion: A Prospective, Multicenter, Randomized Controlled Trial

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorSecond Affiliated Hospital of Nanchang University

About this trial

Background: Patients undergoing arthroscopic surgery for rotator cuff tears with shoulder adhesion often experience significant postoperative pain and stiffness. This study investigates whether adding a long-acting local anesthetic (Liposomal Bupivacaine) to a standard anti-inflammatory steroid injection (Compound Betamethasone) during surgery can improve outcomes.

Methods: This is a prospective, randomized, double-blind, controlled trial. Approximately 70 eligible adult patients will be randomly assigned to one of two groups: (1) the Combination Group, receiving an intra-articular injection of Liposomal Bupivacaine plus Compound Betamethasone after surgery, or (2) the Control Group, receiving Compound Betamethasone alone. Patients and outcome assessors will not know the group assignment.

What participants will do: All participants will receive standard arthroscopic rotator cuff repair and adhesion release. They will be followed for 12 months after surgery, with assessments at multiple time points (from hours to months post-op) to measure pain levels, shoulder function, range of motion, and tendon healing via MRI.

Main Goals: The primary goal is to compare the improvement in UCLA shoulder scores between the two groups at 12 months. Secondary goals include comparing pain scores, other functional scores (Constant-Murley), joint mobility, MRI findings, and safety (complication rates).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • Liposomal Bupivacaine + Compound Betamethasone Injection

    Drug

    Intra-articular injection of a mixture containing Liposomal Bupivacaine and Compound Betamethasone under arthroscopic guidance after standard surgical procedures.

  • Compound Betamethasone Injection

    Drug

    Intra-articular injection of Compound Betamethasone alone under arthroscopic guidance after standard surgical procedures.

Treatment groups

70 Participants
are divided into 2 treatment groups
Group A: Combination Therapy GroupExperimental treatment 1 intervention
Group B: Monotherapy (Control) GroupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in Constant-Murley Shoulder Score

The Constant-Murley score is a composite outcome measure assessing shoulder pain, activities of daily living, range of motion, and strength. Scores range from 0 to 100, with higher scores indicating better function.

Time frame
Baseline, 3 months, and 12 months postoperatively.
2

Visual Analog Scale (VAS) Pain Score at Rest

Pain intensity at rest measured on a 100-mm Visual Analog Scale, where 0 mm represents "no pain" and 100 mm represents "worst pain imaginable."

Time frame
Baseline, 3 months, and 12 months postoperatively.

Secondary outcomes

1

Active Range of Motion (ROM)

Measured in degrees for shoulder forward flexion, abduction, and external rotation using a goniometer

Time frame
Baseline, 3 months, and 12 months postoperatively.
2

American Shoulder and Elbow Surgeons (ASES) Score

A patient-reported outcome measure assessing pain and functional activities. Scores range from 0 to 100, with higher scores indicating better function.

Time frame
Baseline, 3 months, and 12 months postoperatively.
3

MRI Assessment of Tendon Healing

MRI Assessment of Tendon Healing

Time frame
3 months and 12 months postoperatively.
4

Incidence of Treatment-Related Adverse Events

Number and severity of adverse events (e.g., infection, allergic reaction, abnormal bleeding, systemic effects) assessed as related to the study interventions (PRP and/or betamethasone injection).

Time frame
From the time of surgery up to 12 months postoperatively.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.